Menu Search
Equities

EyePoint Pharmaceuticals Inc

PV3B:STU

EyePoint Pharmaceuticals Inc

Actions
  • Price (EUR)5.45
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-35.12%
  • Beta--
Data delayed at least 15 minutes, as of Jun 05 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

EyePoint Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, an investigational sustained delivery intravitreal treatment in Phase II clinical trials. The Company’s commercial product, YUTIQ, is a once-every-three-year treatment for chronic non-infectious uveitis affecting the posterior segment of the eye that utilizes a non-erodible formulation of Durasert. Its commercial product also includes DEXYCU, which is administered as a single dose directly into the surgical site at the end of ocular surgery and is a long-acting intraocular product for the treatment of post-operative inflammation. Its other products include ILUVIEN, Retisert, and Vitrasert.

  • Revenue in USD (TTM)39.79m
  • Net income in USD-102.44m
  • Incorporated2008
  • Employees144.00
  • Location
    EyePoint Pharmaceuticals Inc480 Pleasant St Ste B300WATERTOWN 02472-2468United StatesUSA
  • Phone+1 (617) 926-5000
  • Fax+1 (617) 926-5050
  • Websitehttps://eyepointpharma.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.